NeoGenomics Inc. (NEO)
| Bid | 11.7 |
| Market Cap | 1.60B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -20.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.35 |
| Volume | 3,842,726 |
| Avg. Volume (20D) | 845,586 |
| Open | 12.77 |
| Previous Close | 14.42 |
| Day's Range | 10.69 - 13.30 |
| 52-Week Range | 10.69 - 19.11 |
| Beta | undefined |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fl...
Analyst Forecast
According to 10 analyst ratings, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 56.69% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.
